Impact of Checkpoint Inhibitor Immunotherapy on Infection Risk in Advanced Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study
Clin. Infect. Dis. 2021 Nov 02;73(9)e2697-e2704, AE Malek, M Khalil, R Hachem, AM Chaftari, J Fares, Y Jiang, DP Kontoyiannis, F Fossella, P Chaftari, VE Mulanovich, GM Viola, II RaadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.